Patents by Inventor Julie GERTNER - DARDENNE

Julie GERTNER - DARDENNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric antigen receptor specific for interleukin-23 receptor
    Patent number: 11981739
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) specific for an IL-23 receptor, and to a nucleic acid encoding the same. The present invention further relates to a T cell expressing said CAR, and to the use thereof for treating an autoimmune and/or inflammatory disease or disorder.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: May 14, 2024
    Assignee: SANGAMO THERAPEUTICS FRANCE
    Inventors: Tobias Abel, Julie Gertner-Dardenne, François Meyer
  • CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR INTERLEUKIN-23 RECEPTOR
    Publication number: 20210380704
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) specific for an IL-23 receptor, and to a nucleic acid encoding the same. The present invention further relates to a T cell expressing said CAR, and to the use thereof for treating an autoimmune and/or inflammatory disease or disorder.
    Type: Application
    Filed: April 15, 2019
    Publication date: December 9, 2021
    Applicant: SANGAMO THERAPEUTICS FRANCE
    Inventors: Tobias Abel, Julie Gertner-Dardenne, François Meyer
  • NEW CAR CONSTRUCTS COMPRISING TNFR2 DOMAINS
    Publication number: 20210292389
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof, and to an immune cell expressing said CAR. The present invention further relates to therapeutic methods comprising the administration of an immune cell expressing a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Applicant: SANGAMO THERAPEUTICS FRANCE
    Inventors: Tobias Abel, David Fenard, Julie Gertner-Dardenne, François Meyer
  • Antagonist of the BTLA/HVEM interaction for use in therapy
    Patent number: 10005839
    Abstract: Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: June 26, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Daniel Olive, Christine Pasero, Julie Gertner-Dardenne
  • ANTAGONIST OF THE BTLA/HVEM INTERACTION FOR USE IN THERAPY
    Publication number: 20160122434
    Abstract: The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.
    Type: Application
    Filed: May 16, 2014
    Publication date: May 5, 2016
    Applicant: Centre National de la Recherche Scientifique-CNRS
    Inventors: Daniel Olive, Julie Gertner-Dardenne, Christine Pasero
  • ANTAGONIST OF THE BTLA/HVEM INTERACTION FOR USE IN THERAPY
    Publication number: 20160090420
    Abstract: Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.
    Type: Application
    Filed: February 21, 2014
    Publication date: March 31, 2016
    Inventors: Daniel Olive, Christine Pasero, Julie Gertner-Dardenne
  • COMPOSITIONS FOR TREATING UVEITIS
    Publication number: 20150064206
    Abstract: Compositions including human Treg cells directed to an eye-associated antigen and methods for treating uveitis.
    Type: Application
    Filed: October 27, 2014
    Publication date: March 5, 2015
    Applicant: TXCELL
    Inventors: Arnaud FOUSSAT, Nathalie BELMONTE, Helene ASNAGLI, Julie GERTNER - DARDENNE, Marie JACQUIN, Marie-Francoise HUBERT